Approved VEGF-A specific monoclonal antibodies for the treatment of cancer include Bevacizumab (Avastin for non-small cell lung cancer (NSCLC), glioblastoma, metastatic renal cell-, and cervical cancer) and ramucirumab (Cyramza for gastric, NSCLC and metastatic colorectal cancer). This evidence concerns the gene VEGFA and metastatic colorectal cancer.